NCT07579689 · Phase 4 · NOT YET RECRUITING
Effects of Ginkgo Biloba on Blood Biomarkers in Mild Cognitive Impairment
This trial tests whether Ginkgo biloba extract (240 mg) changes blood markers linked to Alzheimer's, including p-tau217 and NfL, in people with mild cognitive impairment. Half take ginkgo, half take a placebo, for 6 months. Cognition is also checked. It is a Phase 4 trial, meaning the extract is already on the market and researchers are studying its effects further.
You may qualify if
- Age 20 years or older
- Clinical Dementia Rating (CDR) score of 0.5
- Patients clinically indicated for treatment with Ginkgo biloba extract
You're excluded if
- Current use of cholinesterase inhibitors such as donepezil, rivastigmine, or galantamine.
- Refusal to provide informed consent.
- Presence of neurological or psychiatric conditions other than Alzheimer's disease that may affect cognitive function.
- Known hypersensitivity to Ginkgo biloba extract or any of its components.
- Pregnant women.
- Genetic conditions associated with lactose intolerance, including galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.
- Presence of bleeding disorders at screening, or requirement for continuous use of medications that may affect study drug efficacy (e.g., anticoagulants, antiplatelets, thrombolytics, peripheral vasodilators, PGE1 and its derivatives).
- Any condition that, in the opinion of the investigator or study staff, makes the participant unsuitable for the study or unable to comply with study procedures.
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2026-06-26